Improving survival of stage II-III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy.

ABSTRACT:

Background

There is no consistent evidence about the appropriate treatment strategies for gastric signet ring cell carcinoma (GSRC) to improve prognosis. We conducted a population-based study to examine the effects of combined modality therapies on survival outcomes using the Surveillance, Epidemiology, and End Results (SEER) data.

Methods

Analyses included stage II-III primary GSRC patients who were diagnosed between 2006 and 2016. Therapies were categorized as gastrectomy group, adjuvant chemotherapy (CT) group, neoadjuvant radiotherapy (RT) group, and adjuvant chemoradiotherapy (CRT) group. Survival analyses were conducted by Kaplan-Meier method and Cox proportional hazards models and subgrouped by gender, tumor site, stage at diagnosis, and number of lymph nodes removed.

SUBMITTER: Li Y 

PROVIDER: S-EPMC7520351 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature